ZHAO Jianguo,WANG Ting,ZHAO Zhongwei, et al. Clinical study of recombinant human endostatin combined with hepatic arterial chemoembolization in advanced primary hepatic carcinoma[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2016, 46(4): 245-248.
Abstract：Objective: To investigate the clinical efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with transcatheter arterial chemoembolization (TACE) in advanced hepatocellular carcinoma (aHCC) and provide the reference treatment for aHCC. Methods: Sixty-two patients with advanced hepatocellular carcinoma were enrolled from January 2011 to December 2014 in our hospital which were divided randomly into observation group (32 cases) and control group (30 cases) according to the therapeutic methods, the patients of control group were treated with TACE, while the observation group was treated with TACE combined with hepatic dynamic arterial infusion of Endostar. The clinical efficacy and adverse reactions were observed and evaluated between two groups after treatment. Results: The effective rate of observation group was 75%, which was significantly higher than that of the control group with 46.67% (P<0.05), the PFS of observation group was significantly longer than the control group (P<0.05), the survival time was not significantly different (P>0.05) in two groups. No significant difference was found in the incidence of adverse reactions between two groups (P>0.05). Conclusion: Endostar combined with TACE can effectively improve the clinical efficacy and prolong the PFS without more adverse reactions in aHCC, which has important clinical value.
[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] WU H, LIU S, ZHENG J, et al. Transcatheter arterial chemoembolization (TACE) for lymph node metastases in patients with hepatocellular carcinoma[J]. J Surg Oncol, 2015, 112(4): 372-376.
[3] HSIEH M Y, LIN Z Y, CHUANG W L. Serial serum VEGFA, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization[J]. Kaohsiung J Med Sci,2011, 27(8): 314-322.
[4] 王彬彬, 舒琦瑾, 朱国猛. 重组人血管内皮抑制素联合化疗治疗21例晚期非小细胞肺癌的临床观察[J]. 温州医学院学报, 2009, 39(4): 369-371.
[5] QIN S, BAI Y, LIM H Y, et al. Randomized, multicenter,open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
[6] JAIN R K. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers[J]. J Clin Oncol,2013, 31(17): 2205-2218.
[7] MENG M B, JIANG X D, DENG L, et al. Enhanced radioresponse with a novel recombinant human endostatin protein via tumor vasculature remodeling: experimental and clinical evidence[J]. Radiother Oncol, 2013, 106(1): 130-137.
[8] BAO Y, FENG W M, TANG C W, et al. Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization[J]. Hepatogastroenterology, 2012, 59(117): 1566-1568.
[9] 吴之浩. 低氧应激对人肝癌细胞AFP、VEGF、TIMP-1、MMP-9表达的影响[J]. 温州医学院学报, 2012, 42(1): 41-43.
[10] FOLKMAN J. Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action[J]. Exp Cell Res, 2006,312(5): 594-607.
